全文获取类型
收费全文 | 2346篇 |
免费 | 147篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 43篇 |
妇产科学 | 101篇 |
基础医学 | 382篇 |
口腔科学 | 33篇 |
临床医学 | 186篇 |
内科学 | 363篇 |
皮肤病学 | 21篇 |
神经病学 | 246篇 |
特种医学 | 94篇 |
外科学 | 495篇 |
综合类 | 13篇 |
一般理论 | 1篇 |
预防医学 | 117篇 |
眼科学 | 40篇 |
药学 | 67篇 |
中国医学 | 2篇 |
肿瘤学 | 293篇 |
出版年
2023年 | 9篇 |
2022年 | 10篇 |
2021年 | 28篇 |
2020年 | 32篇 |
2019年 | 38篇 |
2018年 | 50篇 |
2017年 | 39篇 |
2016年 | 46篇 |
2015年 | 65篇 |
2014年 | 84篇 |
2013年 | 111篇 |
2012年 | 165篇 |
2011年 | 158篇 |
2010年 | 98篇 |
2009年 | 83篇 |
2008年 | 116篇 |
2007年 | 127篇 |
2006年 | 137篇 |
2005年 | 104篇 |
2004年 | 89篇 |
2003年 | 95篇 |
2002年 | 81篇 |
2001年 | 77篇 |
2000年 | 89篇 |
1999年 | 81篇 |
1998年 | 30篇 |
1997年 | 36篇 |
1996年 | 25篇 |
1995年 | 18篇 |
1994年 | 17篇 |
1993年 | 21篇 |
1992年 | 37篇 |
1991年 | 33篇 |
1990年 | 31篇 |
1989年 | 27篇 |
1988年 | 25篇 |
1987年 | 22篇 |
1986年 | 12篇 |
1985年 | 18篇 |
1984年 | 17篇 |
1983年 | 12篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1979年 | 11篇 |
1978年 | 15篇 |
1977年 | 5篇 |
1975年 | 7篇 |
1971年 | 4篇 |
1925年 | 4篇 |
排序方式: 共有2501条查询结果,搜索用时 31 毫秒
101.
H. Fridborg B. Jonsson P. Nygren K. Csoka K. Nilsson G. Oberg J. Kristensen J. Bergh B. Tholander L. Olsen et al. 《British journal of cancer》1994,70(1):11-17
The semiautomated fluorimetric microculture cytotoxicity assay (FMCA) was used for evaluation of the ability of cyclosporin A (CsA) and its novel non-immunosuppressive derivative SDZ PSC 833 (PSC) to modify the response to doxorubicin or vincristine in vitro in different haematological and solid human tumour types. Primary cultures of 322 tumour samples were analysed. Both cyclosporins showed resistance-modifying activity in all haematological tumours tested, and in solid tumours activity was observed in ovarian carcinoma and childhood tumours. Little or no effect was found in the remaining tumour types, including breast, renal and adrenal cortical carcinomas and adult sarcomas. In most of the responsive cases the interaction between the modifier and the cytotoxic drug was synergistic. There was a tendency to higher activity in samples from previously treated patients, and an inverse relationship between degree of cytotoxic drug resistance and resistance-modifying activity was noted. No difference in potency between CsA and PSC could be discerned. The results indicate differential in vitro resistance-modifying activity of the cyclosporins depending on tumour type. The results also suggest that treatment with resistance modifiers should be considered also for primary therapy of drug-sensitive tumours. Drug resistance assays such as the FMCA may become useful in preclinical evaluation of resistance modifiers. 相似文献
102.
Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. 总被引:33,自引:0,他引:33
OBJECTIVE: To overview the world literature on ovarian hyperstimulation syndrome (OHSS) and modes of prevention and treatment of OHSS. STUDY SELECTION: All the pertinent literature on OHSS, its prevention, and strategies for treatment were reviewed. PREVENTION: Key to prevention is proper identification of the population at risk, which includes women with either the hormonal or the morphological signs of polycystic ovarian disease, high serum estradiol (E2) before human chorionic gonadotropin (hCG) administration (E2 greater than 4,000 pg/mL), multiple follicular response (greater than 35), younger age, and lean habitus. When a high risk situation is recognized, ovulatory dose of hCG may be reduced, avoided (with cycle cancellation), or substituted by gonadotropin-releasing hormone or its agonist. Luteal support with hCG is to be bypassed. To minimize risk of OHSS, endogenous pregnancy-drived hCG may be eluded by judicious cryopreservation of all embryos. Last, follicular aspiration will allow higher levels of E2 and larger number of follicles to be matured with lesser risk of OHSS than conventional ovulation induction without follicular aspiration. TREATMENT: In-house for the severe and intensive care for the critical form. Meticulous fluid and electrolyte balance using both crystalloids and colloids (albumin) until hemoconcentration abates. Paracentesis is indicated for tight ascites, deteriorating kidney functions, and symptomatic relief. Diuretics may be prudently used once hemodilution is achieved. Dopamine drip may be used as a renal rescue, whereas heparin is indicated for thromboembolic phenomena and surgery reserved for abdominal catastrophies. Therapeutic interruption of an early gestation may be lifesaving when all other measures have failed. CONCLUSIONS: Although severe and critical OHSS may not be completely avoided, early recognition of high-risk factors, judicious prevention schemes, and treatment strategies should reduce the complication and long-term sequelae of this iatrogenic syndrome. 相似文献
103.
Jonas Bergh 《Acta oncologica (Stockholm, Sweden)》1995,34(5):669-674
A dose-response relationship has been demonstrated for metastatic human breast cancer. This increased response using moderately increased doses is generally not translated into an improved survival. The use of high-dose therapy to selected patients with metastases/recurrence responding to conventional doses of polychemotherapy may lead to an improved survival tail. Conventional doses of polychemotherapy in the adjuvant setting will reduce the relative mortality by around 25% 10 years after primary diagnosis. The use of high-dose therapy supported by autologous bone marrow stem cells may be markedly more effective in the adjuvant setting, especially to high-risk patients, compared with standard polychemotherapy. Several randomized studies are being planned or have already started in order to answer different aspects of this issue. 相似文献
104.
One hundred ten women with anovulatory infertility (World Health Organization [WHO] group I n = 50, WHO group II n = 60) were given 341 treatment courses with human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG). Additional hCG was given as single or repeated injections during the luteal phase in 205 ovulatory cycles. In WHO group I, the incidence of luteal phase defects was lower and the pregnancy rate higher in cycles with extra hCG administration during the luteal phase than in cycles with no extra hCG. In WHO group II, there was no such difference after supplemental hCG. The abortion rate was the same after cycles with or without extra hCG administration. It is suggested that during ovulation induction with hMG/hCG in anovulatory women with no evidence of endogenous estrogen activity, the luteal phase should be supplemented with additional hCG. 相似文献
105.
Menovsky T de Vries J van den Bergh Weerman M Grotenhuis JA 《Neurosurgery》2002,51(6):1453-5; discussion 1455-6
OBJECTIVE: The in vitro stability of fibrin sealant in cerebrospinal fluid (CSF) was investigated to verify the efficacy of intracranial application of fibrin sealant. METHODS: Human CSF was collected from 11 patients. Fibrin glue spheres (diameter, 5 mm) were incubated in CSF specimens at 37 degrees C. At 2, 4, 8, 24, and 48 hours, the diameter of the spheres was measured and the ultrastructure was evaluated by transmission electron microscopy. A control group consisted of sealant spheres in physiological saline (n = 2). RESULTS: In all CSF samples, the fibrin sealant did not degrade with time. The size, consistency, color, and shape of the sealant remained unchanged, even 48 hours after placement in the CSF. Transmission electron microscopic analysis of the fibrin sealant revealed an amorphous, fibrinous meshwork. No morphological differences existed between fibrin sealant complex placed in the CSF for different time periods and sealant placed in physiological saline. CONCLUSION: Within the limitations of this in vitro study, human CSF has no adverse effects on fibrin sealant in terms of alteration of structure and morphology. Fibrin sealant is stable in a CSF environment and can be effectively used in the cisternal or subarachnoidal space. 相似文献
106.
Suppose “chicken” eggs could be produced by quasi‐chickens—genetically engineered humps of living chicken‐flesh that do nothing but lay eggs. Would there be anything amiss with that? Animal ethicists invoke the notion of animal integrity in order to give intellectual content to the intuition that there would be. On inspection, ‘integrity’ isn't everything its proponents want it to be. Yet there's enough in it to make reasoned argument possible. 相似文献
107.
A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy 总被引:3,自引:0,他引:3
Comi G Roveri L Swan A Willison H Bojar M Illa I Karageorgiou C Nobile-Orazio E van den Bergh P Swan T Hughes R Aubry J Baumann N Hadden R Lunn M Knapp M Léger JM Bouche P Mazanec R Meucci N van der Meché F Toyka K;Inflammatory Neuropathy Cause Treatment Group 《Journal of neurology》2002,249(10):1370-1377
This multicentre randomised double blind crossover trial tested the short term efficacy of intravenous immunoglobulin (IVIg)
2.0 g/kg given over 24 or 48 hours in patients with paraproteinaemic demyelinating neuropathy (PDN). Twenty-two patients were
randomised and completed the trial. After 2 weeks, the overall disability grade decreased during both IVIg treatment and placebo
but neither change was significant nor was the mean difference between the treatment effects. After 4 weeks the overall disability
decreased by a mean of 0.55 [0.67] grades during the IVIg period (p = 0.001) while it was substantially unmodified during
the placebo period. The mean difference between the treatment effects was significant (p = 0.05). Overall during the IVIg
period 10 patients improved and 11 were stable and one got worse. During the placebo period 4 patients improved, 4 deteriorated
and 14 were stable. Many secondary outcome measures, including Rankin scale, time to walk 10 metres, grip strength, sensory
symptoms score were significantly better during IVIg treatment. Two serious adverse events occurred during the trial, both
during placebo treatment. In conclusion the trial showed some short-term benefit of IVIg in about half of the patients confirming
previous observation.
Received: 6 August 2001, Received in revised form: 6 March 2002, Accepted: 12 March 2002
RID="*"
ID="*"The other members of the INCAT group are Jacques Aubry PhD, Institut de Biologie, INSERM Unit 463, 9 Quai Moncousu,
44 035 Nantes, France; Nicole Baumann MD, InSERM Unit 495, Salpetriere Hospital, 75 651 Paris, Cedex 13 France; Robert Hadden
PhD, Michael Lunn, MD, Department of Neuroimmunology, Guy's, King's and St. Thomas' School of Medicine, Guy's Hospital, London
SE1 9 UL, UK; Martin Knapp Phd, Personal Social Services Research Unit, London School of Economics and Political Science,
Houghton Street, London WC2A 1AE, UK; Jean-Marc Léger MD, Pierre Bouche MD, Service d'Eplorations Functionelles de la Salpetriere,
47 Boulevard de l'Hospital, 75 651 Paris, Cedex 13, France; Radim Mazanec CSc, Charles University, 2nd Medical School, University Hospital, V uvalu 84, Prague 5, Czech Republic; Nicoletta Meucci MD, Institute of Clinical Neurology,
University of Milan, Ospedale Maggior-Policlinico, via Sforza, 20 122 Milan, Italy; Frans van der Meché PhD, Department of
Neurology, Erasmus Medical Center Rotterdam, dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands; and Klaus Toyka PhD,
Universitat Würzburg, Josef-Schneider Strasse 2, 97 080 Würzburg, Germany
Correspondence to Giancarlo Comi, MD 相似文献
108.
Baethge C Reischies FM Berghöfer A Baur H Schlattmann P Whybrow PC Bauer M 《Psychiatry research》2002,110(2):117-123
Cognitive disturbance is commonly associated with disorders of the thyroid gland, particularly hypothyroidism, and usually subsides following thyroid hormone replacement therapy. In contrast, the effects of thyroid hormones on cognitive functions in healthy individuals have rarely been studied. The goal of this open-label study was to investigate the short-term effects (duration of administration 45 days on average) of supraphysiological doses of L-thyroxine (L-T(4)) on cognitive performance in young, euthyroid, healthy subjects. Eleven subjects performed a comprehensive neuropsychological test battery, once without and once during administration of supraphysiological doses of L-T(4). There were no significant differences in any of the cognitive test results between the two test sessions. The results of this study do not support our working hypothesis that thyroid hormone can change cognitive performance in young, euthyroid, healthy individuals. 相似文献
109.
Monge-Argiles J Maloteaux J Van Den Bergh P Sindic C 《Neurología (Barcelona, Spain)》2002,17(2):110-112
We report a patient with a peripheral neuropathy as the first symptom of sarcoidosis. The systemic illness was proved by the presence of typic granulomes in the bone marrow. The fact that sarcoidosis is the cause for the neuropathy is supported by the temporary relation and by the good response of all clinical picture to the corticosteroid therapy.Sarcoid neuropathy can rarely be the presenting feature of sarcoidosis. 相似文献
110.
Early onset of treatment efficacy is especially important for severe mania syndromes. Lithium has usually a delayed onset of response, which is disadvantageous for inpatient treatment of severe mania. Valproate is effective in treating acute mania and has sedative properties. It has, however, a response rate of approximately only two thirds. Therefore, the initial combination of valproate and lithium was evaluated in a prospective case series of 12 patients, and a retrospective analysis was carried out for 5 patients in comparison with a pretreatment period when lithium therapy was applied without valproate. Outcome criterion for analysis was the latency of response and remission, as well as the amount of neuroleptics used for additional sedation. Patients had a mania syndrome-severity score comparable with the mean mania score of the bipolar manic patients treated in the same unit. All patients under the combination treatment responded. The response occurred within a shorter time compared with the lithium pretreatment episode, which is statistically marginally significant, and the use of neuroleptic medication could be markedly reduced from 18,601.6 mg chlorpromazine equivalents to 3,927.6 mg (p < 0.025). The initial valproate-lithium combination therapy seems to be a safe and effective way to treat severe mania syndromes in the clinic. 相似文献